Which cancers respond best to chemotherapy, and what it means for you

Some cancers are especially sensitive to chemotherapy, meaning the cancer cells die or shrink markedly with treatment. These include testicular cancer, Hodgkin lymphoma and many fast-growing non-Hodgkin lymphomas, acute leukaemias, particularly in children, and a rare pregnancy-related cancer called gestational trophoblastic disease. Several childhood cancers, such as Wilms tumour of the kidney, also respond strongly. Small cell lung cancer and ovarian cancer usually shrink well at first, although they often come back. In the most sensitive cancers, chemotherapy is typically the main treatment and is often given with the intention of clearing the cancer completely. Sensitivity describes how cancer cells react to the medicines, not a promise about any one person.

Other cancers respond poorly to standard chemotherapy. These include most kidney cancers, melanoma skin cancer, the common types of thyroid cancer, primary liver cancer, many slow-growing brain tumours and some soft tissue sarcomas. Pancreatic cancer and mesothelioma tend to respond only modestly. Many common cancers, such as breast, bowel, stomach, bladder, cervical and head and neck cancers, sit in between: chemotherapy plays an important role, often alongside surgery or radiotherapy, but is rarely used alone. For the less responsive cancers, other treatments usually lead, such as surgery, radiotherapy, targeted medicines, immunotherapy, hormone treatment or radioactive iodine. Chemotherapy may still have a supporting role in some situations, and your oncologist will explain whether that applies to you.

Knowing where your cancer sits on this spectrum can help you understand your plan, but it cannot predict your own outcome. A cancer type that usually responds well does not mean every person's cancer will disappear, and a type that responds less well does not mean nothing can be done. Responsiveness also varies within one cancer type, depending on gene changes, tissue features and how far it has spread. For several less responsive cancers, newer treatments have changed care, and chemotherapy is simply not the main tool. The most useful questions are what chemotherapy is expected to achieve in your case, what the alternatives are, and how your team will judge whether it is working.

The most responsive cancers

Testicular cancer, lymphomas, acute leukaemias and several childhood cancers.

The least responsive cancers

Kidney, melanoma, common thyroid, liver and slow-growing brain tumours.

A pattern, not a prediction

Your own situation depends on far more than cancer type.

It cannot tell you how your own cancer will respond. That depends on many factors beyond cancer type.

It also gives no response or survival figures. Your oncologist can explain what is known for your situation.

Figures you may read online

Numbers from studies describe groups of patients in particular settings, often years ago, and may not match your cancer, your health or current treatment. Reading them alone can cause false hope or needless fear. Ask your oncologist what is realistic for you rather than relying on internet searches.

Shrinking is not the whole story

A tumour that shrinks quickly is encouraging, but shrinkage does not always mean lasting control. Some cancers respond dramatically at first and later return. Your team looks at the overall pattern over time, including symptoms, scans and blood tests, rather than relying on any single result or scan.

Differences within one cancer type

Breast cancer, lung cancer and lymphoma each include several subtypes that respond very differently. For example, a fast-growing breast cancer may respond more strongly to chemotherapy than a slow-growing hormone-sensitive one. Your tissue report explains which subtype you have and helps shape the treatment plan your team recommends for you.

How response is measured

Response is usually judged by scans, blood markers where relevant, physical examination and how you feel. Scans are commonly done after a few cycles. Your oncologist compares results with earlier tests and explains whether the cancer is shrinking, stable or growing, and what that means for the next step in your plan.

When cancers become resistant

A cancer that responds at first can gradually become resistant to a medicine. When this happens, your team may switch to different medicines, add or change to targeted treatment or immunotherapy, or focus on symptom relief. Resistance is common and is not a sign that anyone has done something wrong.

A supporting role still matters

Even in cancers that respond less well, chemotherapy may be used to shrink a tumour before surgery, strengthen radiotherapy or ease symptoms. A modest response can still be meaningful if it relieves pain or breathlessness. Your team will explain the specific purpose in your plan.

Treatment to ease symptoms

For some people, chemotherapy is given mainly to relieve symptoms and improve comfort rather than to clear the cancer. This can still be valuable. It is reasonable to ask how the benefit will be judged and when it would be better to stop and focus on comfort care.

Newer treatments

Targeted medicines and immunotherapy have changed care for several cancers that respond poorly to chemotherapy, such as melanoma and kidney cancer. Tests on your tumour help decide whether these are options. Ask whether such tests have been done on your tissue sample and what the results show.

Children's cancers

Many childhood cancers are more sensitive to chemotherapy than adult cancers. Children are best treated in specialist paediatric units using established protocols, where teams are experienced in balancing treatment intensity with growth, schooling and long-term health. Parents are supported to understand each phase of treatment and what to watch for at home.

Fitness and tolerance

How well a cancer responds is only half the picture. Whether a person can tolerate treatment safely matters just as much. Age, fitness, kidney and heart function and other illnesses all influence which treatment is advised and how intensively it can be given safely in your situation.

Clinical trials

For cancers that respond poorly to existing treatments, clinical trials may offer access to new approaches under careful monitoring. Trials are not suitable for everyone and have eligibility rules. Ask your oncologist whether any trial is relevant to your cancer and where it is available.

Getting a second opinion

If you are unsure whether chemotherapy is the right tool for your cancer, a second opinion is reasonable. Bring your tissue sample report, scans and the proposed plan. A good team welcomes this and will share your records readily with another specialist of your choice, in India or elsewhere.

What to do next

Ask your oncologist what chemotherapy is expected to achieve for your cancer, what the alternatives are, how response will be measured, and whether tumour tests could open other treatment options.